Precigen

PGENNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$2.825 B

$7.89 +2.47%

Close of 22 Sept 2026

Revenue

$9.68M

#3161 by revenue

Earnings

-$250.6M

Loss-making

Shares outstanding

358,035,247

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#79ImmunomeIMNM$2.92B
#80Vicore Pharma Holding ABVCRE$2.86B
#81PrecigenPGEN$2.82B
#82NewAmsterdam PharmaNAMS$2.79B
#83Nurix TherapeuticsNRIX$2.66B

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Precigen, worth $24.7K. Grants and option exercises are excluded.

Nancy H. Agee$24.7K
3,411 shares at $7.23 on 21 Aug 2026 · filed 25 Aug 2026

What if Precigen were worth as much as…

Open the what-if tool →

Gold $30.2T

$84,444.12

Per share 10,703× higher

Bitcoin $1.74T

$4,864.48

Per share 617× higher

Nvidia $5.52T

$15,405.65

Per share 1,953× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for Precigen are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.